Reduced cost for the healthcare sector with surface microdialysis

Important results from the project

The aim has been to technically and commercially prepare Onzurf probe for a market launch. Onzurf probe can now be used in preclinical and clinical research, but for clinical use the Onzurf probe requires to be CE marked. The goal of the project was to have clinical acceptance in order to reach out to intensive care units. We have received very good feedback from the doctor when we perform needs analysis, and we therefore feel that we have good opportunities to introduce Onzurf probe in the health care sector.

Expected long term effects

We have got a good result from the needs analysis that we have carried out with doctors. It has helped us to identify the first target market to be colorectal cancer surgery and created numerous valuable contacts for future studies and sales. We have obtained excellent results from the preclinical studies where we have shown that the product can detect ischemia of the small intestine and stomach. These results have been important to be able to present and discuss when we meet and interviewed doctors.

Approach and implementation

We have worked together with consultants and had clear objectives with the activities, which have worked very well. However, it is difficult to control certain activities that take longer than expected and may cost more. We have followed the schedule well, except the last part concerning the first clinical study. Here, efforts to seek the permission from Läkemedelsverket has taken longer than expected because some parts of the CE marking process should almost be completed and included in the application to the LMV.